We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
Cap. Flow
-$54.5M
Cap. Flow %
-1.47%
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$134M
2
LLY icon
Eli Lilly
LLY
+$114M
3
HOLX
Hologic
HOLX
+$80.8M
4
NEO icon
NeoGenomics
NEO
+$60.6M
5
BIIB icon
Biogen
BIIB
+$55.7M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$103M
3
ABBV icon
AbbVie
ABBV
+$66.8M
4
MDT icon
Medtronic
MDT
+$61.4M
5
BHC icon
Bausch Health
BHC
+$60M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Technology 1.61%
3 Financials 0.67%
4 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
101
Tango Therapeutics
TNGX
$4.35B
$3.41M 0.09%
300,000
– –
TKNO icon
102
Alpha Teknova
TKNO
$260M
$2.37M 0.06%
+100,000
New +$2.53M
DNAB
103
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$2.02M 0.05%
+200,000
New +$2.02M
PROK icon
104
ProKidney
PROK
$316M
$2.02M 0.05%
+200,000
New +$2.02M
AKLI
105
DELISTED
Akili Inc
AKLI
$2.02M 0.05%
+200,000
New +$2.02M
DNAD
106
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$2.02M 0.05%
+200,000
New +$2.02M
FLYW icon
107
Flywire
FLYW
$1.99B
$1.84M 0.05%
+50,000
New +$1.68M
CLVS
108
DELISTED
Clovis Oncology, Inc.
CLVS
$1.58M 0.04%
+271,726
New +$1.59M
OMIC
109
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.37M 0.04%
+1,667
New +$1.29M
NPCE icon
110
Neuropace
NPCE
$522M
$952K 0.03%
+40,000
New +$928K
NUVB.WS
111
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$260K 0.01%
99,999
– –
MSACW
112
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$58K ﹤0.01%
+57,770
New +$45.8K
AFMD
113
DELISTED
Affimed
AFMD
– –
-129,600
Closed -$10.3M
AMWL icon
114
American Well
AMWL
$185M
– –
-3,513
Closed -$1.22M
ANNX icon
115
Annexon
ANNX
$841M
– –
-70,000
Closed -$1.95M
ARGX icon
116
argenx
ARGX
$55.6B
– –
-20,000
Closed -$5.51M
LONA
117
LeonaBio Inc
LONA
$69.1M
– –
-167,785
Closed -$30.9M
AUPH icon
118
Aurinia Pharmaceuticals
AUPH
$1.96B
– –
-1,784,000
Closed -$23.2M
AZN icon
119
AstraZeneca
AZN
$263B
– –
-1,825,250
Closed -$182M
BHC icon
120
Bausch Health
BHC
$1.67B
– –
-1,891,300
Closed -$60M
BOLT icon
121
Bolt Biotherapeutics
BOLT
$7.63M
– –
-32,715
Closed -$21.5M
BVS icon
122
Bioventus
BVS
$843M
– –
-1,254,333
Closed -$19.2M
CGEM icon
123
Cullinan Oncology
CGEM
$1.07B
– –
-707,359
Closed -$29.5M
CI icon
124
Cigna
CI
$77B
– –
-135,000
Closed -$32.6M
COGT icon
125
Cogent Biosciences
COGT
$6.91B
– –
-417,710
Closed -$3.67M
2 3 4
5
6

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2021 Portfolio in Review

As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology and Financials.

  • Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
  • Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
  • Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
  • Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
  • Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
  • Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
  • Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.